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Neurological outcomes following spinal cord injury (SCI) are currently difficult to predict. 
Whilst the initial American Spinal Injury Association (ASIA) Impairment Scale (AIS) grade 
can give an estimate of outcome, the high remaining degree of uncertainty has stoked 
recent interest in biomarkers for SCI. This study aimed to assess the prognostic value of 
routinely measured blood biomarkers by developing prognostic models of AIS scores at 
discharge and 12-months post-injury. Routine blood and clinical data were collected from 
SCI patients (n=417) and blood measures that had been assessed in less than 50% of 
patients were excluded. Outcome neurology was obtained from AIS and Spinal cord 
independence measure III (SCIM-III) scores at discharge and 12-months post-injury, with 
motor (AIS) and sensory (AIS, touch and prick) abilities being assessed individually. Linear 
regression models with and without elastic net penalization were created for all outcome 
measures. Blood measures associated with liver function such as alanine transaminase 
were found to add value to predictions of SCIM-III at discharge and 12-months post-injury. 
Furthermore, components of a total blood count including hemoglobin were found to add 
value to predictions of AIS motor and sensory scores at discharge and 12-month post-
injury. These findings corroborate the results of our previous preliminary study and thus 
provide further evidence that routine blood measures can add prognostic value in SCI, and 
that markers of liver function are of particular interest. 
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Spinal cord injury (SCI) is damage to the spinal cord due to trauma, degeneration or 
disease that results in a temporary or permanent change to its neurological function. The 
global age-standardized incidence of SCI has been estimated to be 13 per 100,000, 
whereas the age-standardized prevalence was estimated to be 368 per 100,000.1 With 
respect to the United Kingdom, it has been estimated that over 1000 new SCIs occur each 
year, and that 40,000 people are living with SCI.2 The majority of SCIs have historically 
been traumatic in nature, most commonly as a result of vehicular accidents, falls, violence 
and sports, but more recently non-traumatic SCI, usually as a result of infection or cancer, 
has been increasing in prevalence.3,4 
The lifetime cost of SCI in the UK is estimated to be £1.12 million (mean value) per case, 
with the total cost of SCI in 2016 in the UK being  £1.43 billion.5 SCI can lead to secondary 
conditions that increase morbidity and mortality, including respiratory complications, deep 
vein thrombosis, muscle spasms, urinary tract infections, osteoporosis, pressure ulcers, 
risk of fracture, and chronic pain. Furthermore, patients with SCI are often rendered 
dependent on caregivers and show markedly higher rates of mental illness relative to the 
general population.6 
There is a challenge in the development of novel therapeutic interventions for SCI, with 
only four large-scale clinical trials having been tested in acute SCI, three of which 
evaluated methylprednisolone and one evaluated GM-1 ganglioside.7–10 This is due to the 
SCI population being inherently heterogeneous and experiencing a highly variable degree 
of “natural” recovery.11 Currently, the best predictor of neurological outcome is the initial 
measure of neurologic impairment, as assessed with the International Standards for 
Neurological Classification of SCI (ISNCSCI) examination.12 However, the ISNCSCI exam was 
not intended to be predictive of functional recovery, and it has been found that changes in 
American Spinal Injury Association Impairment scale (AIS) grade do not necessarily indicate 
meaningful changes to daily living for patients.13 Robust SCI biomarkers could help stratify 
patients such that their baseline functional recovery could be predicted, allowing any 
potential novel therapies to be properly assessed, thus accelerating research and clinical 
trials in particular via covariate adjustment.14 A reliable prognostic model of SCI would also 












































































































































































































allow healthcare providers to better plan patient care, relieve patients of potentially 
damaging psychological uncertainty, and could highlight new avenues of research.15 Whilst 
relatively few studies have sought to identify prognostic biomarkers for SCI, recent years 
have seen some early/discovery phase publications.16–19 These preliminary studies have 
largely focused on biomarkers in cerebral spinal fluid during the acute phase of injury, with 
little information regarding the chronic or recovery phase. Even among these studies 
however, there has been little investigation as to the value of blood biomarkers in SCI at 
any injury phase, despite success in other fields, including cancer, traumatic brain injury, 
and Alzheimer’s disease.20–22 
We previously published a preliminary study that highlighted the value of routinely 
measured blood analytes in prognostic models of SCI, and demonstrated that some blood 
measures, particularly markers of liver function, added modest, but statistically significant, 
value to predictions of 3- and 12-month ISNSCI AIS motor and sensory scores.23 In this 
study, we have validated our findings in another, independent and larger SCI cohort. We 
have further developed alternative more robust methods of modelling and have 
demonstrated that similar markers, including alanine transaminase (ALT) and gamma-
glutamyl transferase (GGT) add value not only when predicting AIS scores at discharge and 
12-months, but also with regards to SCIM outcomes. 
Method 
Patient and model feature summary 
We retrospectively studied the electronic health records of 500 patients who had been 
admitted to the Midlands Centre for Spinal Injuries (MCSI) in the last 10 years (Table 1). 
Access to these records was ethically approved by the National Research Ethics Service 
[NRES] Committee North West Liverpool East [11/NW/0876] and NRES Committee West 
Midlands, Staffordshire [13/WM/0158]. Following the exclusion of patients that had been 
admitted over 6 months post-injury, 73 individuals were removed from further analysis. 
The remaining 417 patients had their initial blood sample taken at a mean of 31 ± 30 
(standard deviation) days post-injury. Blood measures that had been assessed in less than 












































































































































































































50% of the patient cohort  were excluded. The remaining blood measures included 
adjusted calcium estimate, alkaline phosphatase, C-reactive protein (CRP), hematocrit, 
hemoglobin, mean cell hemoglobin, mean cell volume, mononucleocytes, platelets, 
potassium, red blood count, red blood distance width and white blood count (WBC). 
Routine blood analyses were conducted in the Hematology and Biochemistry department 
located at the Robert Jones and Agnes Hunt Orthopedic Hospital. Hematology analyses 
were performed on either a Beckman Coulter LH-500 (Beckman Coulter, High Wycombe) 
or a Sysmex XN-1000 (Sysmex America, IL). Biochemical analyses used VITROS slides (dry 
multi-layered chemistry slides) in conjunction with the VITROS 5,1 FS Chemistry System 
(Ortho Clinical Diagnostics, New Jersey, USA) to measure albumin, ALT, calcium, creatinine, 
GGT, potassium, magnesium, sodium, total bilirubin, total protein, and urea. 
In addition to AIS overall grade, AIS motor, sensory touch and sensory pin prick scores 
were recorded at admission, discharge (mean 136 days post-injury ± 72) and 
approximately 12 months post-injury (mean 424 days post-injury ± 147). Spinal cord 
independence measure III (SCIM-III) assessments were also recorded at these same time 
points.24 The SCIM assessment is a disability scale developed to quantify the ability of SCI 
patients to perform basic activities of independent daily living, including self-care (feeding, 
bathing and dressing), respiration and sphincter management, and mobility (Figure 1).25,26 
Additional information that may impact neurological recovery and/or the assessed blood 
measures were included. The incidence of diabetes (types I and II), smoker and alcohol 
drinking status were recorded as binary. The neurological level of the injury was recorded 
as being cervical, thoracic, lumbar or sacral. Details were recorded as to whether the injury 
was traumatic, and whether there were any fractures at the injury site. Age at injury in 
years, gender and the time between injury and the first blood tests in days were also 
included. Medications that patients were prescribed were also collected, however after 
filtering to drugs at least 50% of patients were given, the remaining drugs were either 
painkillers or anti-spasm medication. As the inclusion of this drug data would have added a 
large number of variables to the model, and they correlated strongly with initial injury 
severity, this data was not included in the modelling process. 













































































































































































































Data analyses were performed with the statistical programming language R version 3.6.3 
(2020-02-29).27–40 Missing blood measures were median imputed, then scaled and 
centered. Less than 21% of the initial and discharge AIS/SCIM scores were missing, 
whereas 50-60% of the 12-month scores were missing (Table S1). These missing AIS grades 
or scores were imputed with either last observation carried forwards (LOCF) or next 
observation carried backwards (NOCB) where relevant. LOCF and NOCB were used as it is 
unusual for AIS or SCIM scores to have decreased over time in SCI patients. These scores 
typically only either remain largely unchanged, or improve with time.41 Therefore, the use 
of this imputation effectively assumes that in cases of missing score data, the patients’ 
score did not change. This assumption can only worsen model performance, as opposed to 
giving rise to the overly optimistic models that could be generated by more complex 
multiple imputation techniques. Additionally, we have been advised that most cases 
where neurological assessment was missing at admission or discharge is due to a transition 
from Frankel scoring to AIS. In the case of missing 12-month assessments, this is most 
commonly due to a given patient not attending their appointment or having received 
follow up from a different hospital (Table S1). 
As the number of model features was relatively high compared to the number of 
observations (45 features and 417 observations), linear regression with elastic net 
penalization was performed in addition to linear regression without any penalization. 
Elastic net penalization is a hybrid of ridge regression, whereby the penalty term shrinks 
predictor effect equally and never to 0, and least absolute shrinkage & selection operator 
(LASSO), whereby the penalty term shrinks each predictor differently and allows variables 
to be removed entirely by shrinking coefficients to 0.42,43 Put simply, elastic net reduces 
the impact of less important model features and can effectively eliminate features 
entirely, thus performing variable selection during the model building process, as opposed 
to other methods such as backward variable selection, which are conducted before model 
building and eliminate features based on co-linearity. Elastic net penalization has been 
previously found to perform well in models with numerous predictors and in the presence 
of correlated predictors.44 












































































































































































































Eight independent models were generated, with and without elastic net penalization, to 
determine if the features could predict four outcome measures: AIS motor, AIS sensor 
touch, AIS sensor prick and SCIM, at two time points: discharge and 12-months post-injury. 
The data was randomly split 80-20%, whereupon 80% was used for training the model and 
the remaining 20% was used to test the models performance. To reduce model optimism, 
internal validation was performed by 10-fold cross validation.45 
Results 
Multiple regression models of the AIS motor and sensory scores, and of SCIM, at discharge 
(mean 136 ± 72 days post-injury) and approximately 12 months post injury (mean 424 ± 
147 days post-injury) were built (Tables S2, S3 & S4). In addition to standard linear 
regression models (LRM), generalized linear models (GLM) with elastic net penalization 
were also performed. The modelling techniques performed similarly (GLM 
                                               range 0.53-0.76 and RMSE range 
12-19) (Figures 1 & 2) 
Model features 
With respect to model features, AIS measures of initial neurological function were the 
most consistently conserved features and the most powerful predictors of outcome 
measures for the generalized models. Initial SCIM was also included for all the models of 
outcome, except those relating to discharge sensory prick, touch and 12-month sensory 
touch. The blood markers, ALT, albumin, alkaline phosphatase, CRP, creatinine, GGT, 
hematocrit, hemoglobin, mean cell hemoglobin, mean cell volume, monocytes, platelets, 
potassium, total bilirubin, total protein, urea and WBCwere significant (P-Value < 
0.05)/included in one or more models (Table 2). 
For the linear regression models, the AIS grade on admission was the only feature that was 
statistically significant (P-Value < 0.05) in all models except 12-month SCIM. The initial 
measure of the model target, so the initial AIS motor score for the models of discharge and 
12 month AIS motor for example, was also significant in all models. Other significant 
features that were not blood measures included diabetes and smoker status, age at injury, 












































































































































































































time until first blood test from injury, the neurological level of injury, gender, and the 
presence of fracture at the injury site. Regarding blood measures, urea, monocytes, mean 
cell hemoglobin, mean cell volume, hematocrit and hemoglobin were all significant in one 
or more of the models (Table 2). 
Model performance 
With respect to model predictions, both modelling techniques performed similarly when 
predicting against the test data (Figures 3 & S1-8). 
Discussion 
Penalized GLM was compared to linear regression in the study due to the sample size. 
Whilst there has long been a dogma that 10 events per variable (EPV) is sufficient, more 
recent studies have argued that there is no rational for this.46,47 As there were 417 patients 
and 45 variables, we also investigated the impact of modelling with and without variable 
selection in the form of elastic net penalization. 
In this study, a standard linear regression model with no variable selection performed very 
similarly to GLM with elastic net penalization with respect to R2 and RMSE, though the R2 
of GLM was slightly higher and RMSE slightly lower for all model targets (Figures 1 & 2). 
This suggests that elastic net penalization does not provide a substantial boost to overall 
model performance at this sample size relative to linear regression. However, there was a 
difference in the variables each model utilized. 
Regarding  blood measures in the linear regression models, urea, total bilirubin and 
creatinine were significant predictors for one or more outcomes. Creatinine was predictive 
of discharge SCIM and sensor touch. Total bilirubin was predictive motor, sensor prick and 
sensor touch at month-12, suggesting it is predictive of longer term outcomes. Urea, which 
is typically used as an indicator of kidney function, but may also be altered due to 
hydration status, was predictive of discharge SCIM in the standard linear regression model, 
but was predictive of month-12 sensor touch in the penalized models.  
 












































































































































































































With the exception of  time to first blood test from injury, all of the same features were 
included in the penalized models and the linear regression models, but other related 
bloods were also included, such as mean cell hemoglobin, mean cell volume, hematocrit, 
hemoglobin, platelets and WBC, which are the components of a complete blood count. 
The complete blood count is likely related to the initial injury severity via blood loss due to 
bony soft tissue or visceral injury, gastrointestinal bleeding, and/or surgery.48 Monocytes 
were included in all GLM models at both time points except month-12 SCIM. Similar to the 
components of the complete blood count, monocytes levels may be indicative of anemia 
(if low), but have also been associated with hepatitis and inflammatory diseases (if 
high).49,50 Estimated serum creatinine, based on glomerular filtration rates, are typically 
used in the evaluation of renal function.51,52 SCI patients have also been found to have an 
increased risk of renal deterioration and are recommended to receive lifelong, regular 
renal and upper urinary tract examinations after injury.53,54 SCI has been found to lead to 
systemic inflammation which can in turn cause secondary organ complications, including in 
the liver, kidneys and lungs, which may explain why these blood measures are useful in 
predicting outcome.55-58 
Some studies have found SCI to induce hepatic lipid deposition and inflammation, within 3 
months of injury in rats, which is symptomatic of non-alcoholic steatohepatitis (NASH), the 
hepatic presentation of metabolic syndrome.59,60 Importantly, the blood measures 
associated with liver function (alanine transaminase, alkaline phosphatase, CRP, GGT and 
total bilirubin) highlighted in this study were also found to be significantly predictive of AIS 
scores in our preliminary study. Two factors “liver function”, consisting of alanine 
transaminase, alkaline phosphatase and GGT and “liver function and inflammation” 
consisting of CRP and total bilirubin added statistically significant value to models of AIS 
touch and pain scores at 3-months post injury, and AIS motor and pain scores at 12-
months.23,61,62 Total bilirubin in particular was included in 5 out of 8 penalized models and 
was significant in 3 of the non-penalized models. This provides further evidence that liver 
function is relevant to neurological recovery in SCI. 
Interestingly, alanine transaminase, alkaline phosphatase, GGT and albumin were only 
retained in the models of SCIM. This could be because these markers indicate liver status, 












































































































































































































which in turn typically reflects general metabolic health. Therefore, aberrant ALT and GGT 
values may be a proxy measure of poor metabolic health or systemic inflammation. 
Diabetes status was also significant in 6 of the 16 models built in this study, which may also 
reflect the relevance of general metabolic health in recovery. Metabolic syndrome is also 
more common in SCI patients than the general population and, SCI patients consequently 
have an increased risk of diabetes, stroke and heart disease.60,63–65 
Serum albumin has also been previously found to be significantly predictive of AIS grade 
improvement up to 52 weeks.66 Platelets and gender were also only retained in models of 
SCIM. Previous studies contradict this result and have suggested that gender does not 
significantly correlate with functional neurology or independence.67,68 However, it may be 
that some elements of the SCIM questionnaire are easier for males, such as self-
catheterization, and so they are able to obtain slightly higher scores than females, even at 
a similar level of neurological function (as determined by AIS scores). Interestingly, surgery 
was only found to be a significant predictor of SCIM at both time points in the GLM 
models. This suggests surgery does not have a substantial influence on AIS outcomes. It 
should be stressed that this hospital favors a conservative approach to care of SCI patients, 
only choosing to operate in the most extreme cases and so both the rate and type of 
surgery given to this cohort likely differ from other spinal centers.69 Therefore, external 
validation with data from centers with the more common surgical approach to SCI care is 
needed to more fully establish the role of surgery in predicting outcomes.70, 71 
Whether the injury was traumatic or not was not retained in any model. Despite the very 
distinct pathophysiology of non-traumatic injuries, this data suggests trauma status is not 
a strong predictor of AIS motor or sensor score outcomes.72 Prior studies have also 
observed similar functional outcomes between traumatic and non-traumatic injuries.73 
Further research is needed to establish the role of the liver in SCI, particularly whether the 
liver is causally implicated in functional recovery, or if it is merely a proxy indicator of 
systemic inflammation inhibiting healing. Once this association is established, clinicians 
could consider monitoring the liver function of SCI patients more closely, perhaps 
attempting to restore/maintain healthy parameters in the interim by minimizing the use of 
hepatotoxic drugs where possible. 












































































































































































































An important limitation of this study is the volume and completeness of the data used in 
model building. A larger sample size will always lead to a more robust and widely 
applicable model, and whilst there was enough to build linear regression models, a larger 
dataset (>5000) could allow for robust logistic regression models to predict a change in AIS 
grade. Furthermore, the data used here contained missing values, and whilst these were 
imputed to have minimal effect on model performance, it is still preferable to have a 
complete dataset. Models of 12-month outcomes were built using discharge and 
admission scores with the same methodology, and whilst these models performed better 
overall, the proportion of missing values at the 12-month time point, sample size and more 
modest difference in average AIS score between discharge and 12-months may cause 
overfitting, therefore this data was not included. Finally, an independent external 
validation of these models on separate data, potentially with a cohort with more typical 
surgical based care, would be desirable, particularly for the GLMs as it is difficult to obtain 
robust estimates of bias in penalized regression, making standard errors and confidence 
intervals inappropriate.74 
Conclusion 
The results from this study suggest that routinely measured blood analytes can provide 
useful prognostic information for AIS scores and SCIM assessments up to 12-months post-
injury, reinforcing the findings of our preliminary study.23 Markers of liver function are of 
particular interest, and rehabilitation clinicians should consider the maintenance of liver 
health as a priority as it may be relevant to neurologic functional recovery. More research 
is needed to establish whether or not the relationship between SCI recovery and liver 
function is causal. Ultimately these finding need to be validated on a larger independent 
cohort before any firm clinical recommendations can be made. 
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Table 1. Patient demographics 
  Number of SCI patients 
(n out of 417) 
Percent 
Age at injury (Median 
years) 
56±28    
Length of stay 
(Median days) 
100±66    
Fracture 225 53   
Surgery 217 51   
Traumatic injury 319 75   
Type 1 diabetes 5 1   
Smoker Type 2 diabetes 44 10   
No 281 66   
Yes 52 12   
Alcohol consumption Unknown 84 20   
No 181 42   
Yes 152 36   
Gender Unknown 84 20   
Male 283 66   
Time from injury (Median Female 134 31   












































































































































































































days) First blood test 22±35    
Admission 20±34    
Discharge 128±82    
Neurological level of injury Month-12 assessment 390±103    
Cervical 244 57   
Lumbar 30 7   
Sacral 1 0   
Admission AIS grade Thoracic 142 33   
A 108 25   
B 48 11   
C 151 35   
D 110 26   
AIS conversion  
from admission to 12-
Months 
A-B 4 0.9 
A-C 4 0.9 
A-D 1 0.2 
B-C 11 2.6 
B-D 4 0.9 
C-D 47 11   












































































































































































































C-E 1 0.2 
D-E 1 0.2 
AIS conversion  
from admission to discharge 
A-B 4 0.9 
A-C 4 0.9 
B-C 13 3   
B-D 4 0.9 
C-D 47 11   
D-E 3 0.7 
  
  












































































































































































































Table 2. Counts of model feature occurrence. For unpenalised linear regression (LRM) 
statistically significant (P-value < 0.05) features are included. For penalised models (GLM) 
features that were not penalised to 0 are induced 
Model feature GLM LRM 
(Intercept) 8 8 
Admission AIS gradeB 2 2 
Admission AIS gradeC 6 6 
Admission AIS gradeD 6 6 
Age at injury 2 2 
Alanine Transaminase (u/L) 2 0 
Albumin (g/L) 1 0 
Alkaline Phosphatase (u/L) 1 0 
C-Reactive Protein (mg/L) 1 0 
Creatinine (umol/L) 4 2 
Drinking yes 5 1 
Fracture 1 1 
Gamma GT (u/L) 1 0 
Haematocrit (L/L) 4 0 
Haemoglobin (g/L) 5 0 
Initial motor 8 6 
Initial scim 4 2 












































































































































































































Initial sensor prick 8 2 
Initial sensor touch 5 3 
Lumbar injury 2 0 
Mean Cell Hb (pg) 4 0 
Mean Cell Volume (fL) 6 0 
Monocytes (10*9/L) 7 0 
Neuro level T 1 0 
Platelets (10*9/L) 1 0 
Potassium (mmol/L) 1 0 
Sex 2 1 
Smoker status known 1 0 
Smoker status unknown 0 1 
Surgery 1 0 
Time to first blood test (Days) 0 2 
Total Bilirubin (umol/L) 5 3 
Total Protein (g/L) 1 0 
Type 1 diabetes 2 0 
Type 2 diabetes 3 1 
Urea (mmol/L) 1 1 
White blood count (10*9/L) 1 0 












































































































































































































Figure 1. Boxplots of AIS score change from admission 
  



































































































































































































































































































































































































































Figure 3. Root mean square error (RMSE) for linear regression models with and without 
elastic net penalisation (GLM and LRM respectively) of neurological outcome at discharge 









































































































































































































































































































































































































































Supplementary Table 1. Missing AIS and SCIM scores (out of 431 total patients). 
 Total number of missing values Percent missing 
Initial sensor prick 3 1 
Initial sensor touch 3 1 
Initial motor 4 1 
Discharge scim 37 9 
Initial scim 44 11 
Discharge motor 73 18 
Discharge sensor prick 87 21 
Discharge sensor touch 87 21 
Month-12 scim 231 55 
Month-12 motor 252 60 
Month-12 sensor touch 255 61 
Month-12 sensor prick 256 61 
  
  












































































































































































































Supplementary Table 2. Linear regression model coefficients with elastic net penalisation 
Model Variable Coefficients 
Discharge motor (Intercept) 14.4      
Haemoglobin (g/L) 0.56     
Mean Cell Hb (pg) 0.343    
Mean Cell Volume (fL) 0.297    
Monocytes (10*9/L) 0.714    
Admission ASIAC 8.12     
Admission ASIAD 7.27     
Alcohol Drinking status 0.665    
Discharge sensor prick Initial motor 0.681    
Initial sensor prick 0.0847   
Initial sensor touch 0.00759  
Initial scim 0.0483   
(Intercept) 16.7      
Creatinine (umol/L) 0.215    
Haemoglobin (g/L) 0.98     
Monocytes (10*9/L) 0.936    
Total Bilirubin (umol/L) 0.961    
Type 2 diabetes 0.13     












































































































































































































Discharge sensor touch Admission ASIAC 5.97     
Admission ASIAD 1.51     
Initial motor 0.165    
Initial sensor prick 0.564    
Initial sensor touch 0.13     
(Intercept) 21.3      
Creatinine (umol/L) 1.05     
Haematocrit (L/L) 1.55     
Mean Cell Volume (fL) 0.225    
Monocytes (10*9/L) 1.11     
Total Bilirubin (umol/L) 0.758    
Discharge SCIM Type 2 diabetes 1.96     
Admission ASIAB 2.85     
Admission ASIAC 10.3      
Admission ASIAD 5.24     
Lumbar injury 0.489    
Alcohol Drinking status 0.046    
Initial motor 0.064    
Initial sensor prick 0.0308   
Initial sensor touch 0.654    












































































































































































































(Intercept) 24.1      
Alanine Transaminase (u/L) 0.743    
Albumin (g/L) 0.000168 
Alkaline Phosphatase (u/L) 0.732    
Creatinine (umol/L) 1.48     
Gamma GT (u/L) 0.189    
Mean Cell Volume (fL) 0.899    
Monocytes (10*9/L) 0.0577   
Platelets (10*9/L) 0.249    
Total Protein (g/L) 0.775    
White blood count (10*9/L) 0.697    
Type 1 diabetes 4.86     
Month-12 motor Neuro level T 0.984    
Sex 1.97     
Alcohol Drinking status 1.88     
Fracture 0.697    
Surgery 1.27     
Initial motor 0.263    
Initial sensor prick 0.0828   
Month-12 sensor prick Initial scim 0.577    












































































































































































































(Intercept) 20.5      
Creatinine (umol/L) 0.016    
C-Reactive Protein (mg/L) 0.868    
Haematocrit (L/L) 0.00315  
Haemoglobin (g/L) 1.64     
Mean Cell Hb (pg) 0.0101   
Mean Cell Volume (fL) 0.442    
Monocytes (10*9/L) 0.852    
Potassium (mmol/L) 0.404    
Month-12 sensor touch Total Bilirubin (umol/L) 0.386    
Type 1 diabetes 3.37     
Admission ASIAB 0.277    
Admission ASIAC 9.01     
Admission ASIAD 9.39     
Smoking yes 0.699    
Alcohol Drinking status 1.75     
Initial motor 0.576    
Initial sensor prick 0.126    
Initial scim 0.027    
(Intercept) 14.3      












































































































































































































Haematocrit (L/L) 0.425    
Month-12 SCIM Haemoglobin (g/L) 0.74     
Mean Cell Hb (pg) 0.209    
Monocytes (10*9/L) 0.986    
Total Bilirubin (umol/L) 1.12     
Admission ASIAC 6.03     
Admission ASIAD 1.44     
Lumbar injury 1.45     
Age at injury (Median years) 0.0507   
Initial motor 0.193    
Initial sensor prick 0.423    
Initial sensor touch 0.229    
(Intercept) 15.5      
Haematocrit (L/L) 0.779    
Haemoglobin (g/L) 0.777    
Mean Cell Hb (pg) 0.00573  
Mean Cell Volume (fL) 0.07     
Monocytes (10*9/L) 1.17     
Total Bilirubin (umol/L) 0.672    
Urea (mmol/L) 0.162    












































































































































































































Type 2 diabetes 1.87     
Admission ASIAC 8.83     
Admission ASIAD 2.44     
Age at injury (Median years) 0.0249   
 Alcohol Drinking status 0.65     
 Initial motor 0.0837   
 Initial sensor prick 0.0852   
 Initial sensor touch 0.632    
 (Intercept) 23.9      
 Alanine Transaminase (u/L) 0.168    
 Mean Cell Volume (fL) 0.136    
 Sex 1.47     
 Initial motor 0.221    
 Initial sensor prick 0.0909   
 Initial scim 0.591    
  
  












































































































































































































Supplementary Table 3. Final elastic net model parameters. Alpha is a value between 0 and 
1, where 0 is pure ridge regression, 1 is pure LASSO and values between are a mixture of 
both. Lambda is the shrinkage factor applied to model coefficients 
Model target alpha lambda 
Discharge motor 1   0.679 
Discharge sensor prick 1   0.738 
Discharge sensor touch 0.6 0.718 
Discharge SCIM 0.6 0.632 
Month-12 motor 1   0.636 
Month-12 sensor prick 0.4 1.67  
Month-12 sensor touch 1   0.722 
Month-12 SCIM 1   1.47  
  
  












































































































































































































Supplementary Table 4. Linear regression model coefficients without elastic net 
penalisation 





Discharge motor (Intercept) 19.6   5.02   3.91 0.000117 
Admission ASIAC 12.4   2.54   4.89 1.64e-06 
Admission ASIAD 11.2   3.41   3.3  0.0011   
Discharge sensor 
prick 
Initial motor 0.705 0.0635 11.1  4.15e-24 
(Intercept) 14.8   5.21   2.85 0.00472  
Total Bilirubin (umol/L) 1.4   0.596  2.36 0.0192   
Admission ASIAC 9.91  2.64   3.76 0.000209 
Initial motor 0.21  0.0659 3.19 0.00158  
Discharge sensor 
touch 
Initial sensor prick 0.555 0.0611 9.09 1.59e-17 
(Intercept) 22.4   4.54   4.94 1.32e-06 
Creatinine (umol/L) 1.84  0.935  1.97 0.0496   
Admission ASIAB 6.96  2.46   2.83 0.00492  
Admission ASIAC 14.5   2.3    6.29 1.17e-09 
Admission ASIAD 9.96  3.09   3.23 0.00139  
Initial sensor touch 0.664 0.0537 12.4  1.67e-28 
(Intercept) 24.1   5.79   4.17 4.06e-05 












































































































































































































Creatinine (umol/L) 2.96  1.19   2.48 0.0138   
Discharge SCIM Urea (mmol/L) -2.72  1.25   -2.18 0.03     
Type 2 diabetes -6.68  2.85   -2.34 0.0198   
Admission ASIAB -7.26  3.14   -2.32 0.0213   
Admission ASIAD -10.6   3.94   -2.68 0.0078   
Age at injury (Median 
years) 
-0.208 0.0616 -3.38 0.000827 
Time to first blood test 
(Days) 
-0.109 0.0393 -2.78 0.00586  
Smoking unknown -5.18  2.36   -2.2  0.0289   
Initial motor 0.301 0.0733 4.11 5.19e-05 
Initial scim 0.591 0.0605 9.78 1.02e-19 
(Intercept) 25.7   6.1    4.2  3.51e-05 
Month-12 motor Admission ASIAC 14.6   3.09   4.72 3.67e-06 
Admission ASIAD 15.6   4.15   3.76 0.000206 
Initial motor 0.571 0.0772 7.39 1.52e-12 
(Intercept) 13.1   5.59   2.35 0.0194   
Total Bilirubin (umol/L) 1.57  0.64   2.45 0.0149   
Admission ASIAC 11.3   2.83   3.99 8.25e-05 
Month-12 sensor Admission ASIAD 7.75  3.8    2.04 0.0422   












































































































































































































prick Fracture -4.39  2.19   -2    0.0461   
Initial motor 0.209 0.0708 2.95 0.00344  
Initial sensor prick 0.434 0.0656 6.62 1.75e-10 
Initial sensor touch 0.173 0.0661 2.62 0.00922  
(Intercept) 17.6   5.33   3.3  0.00111  
Total Bilirubin (umol/L) 1.37  0.611  2.25 0.0255   
Admission ASIAC 13.8   2.7    5.1  6.06e-07 
Month-12 sensor 
touch 
Admission ASIAD 8.18  3.62   2.26 0.0248   
Drinker status 3.57  1.66   2.15 0.0321   
Initial sensor touch 0.618 0.0631 9.79 9.19e-20 
(Intercept) 20.9   6.47   3.23 0.00139  
Sex 4.73  2.2    2.15 0.032    
Age at injury (Median 
years) 
-0.226 0.0687 -3.29 0.00111  
Time to first blood test 
(Days) 
-0.103 0.0439 -2.36 0.0191   
Initial motor 0.275 0.0819 3.36 0.000896 
Month-12 SCIM Initial scim 0.595 0.0675 8.81 1.17e-16 
 
